[In vitro and in vivo targeting therapy of immunoliposomes against human gastric cancer].
Nine kinds of antineoplastic agents and 2 boron-10 compounds were encapsulated respectively into the immunoliposomes targeted with monoclonal antibody, MGb2, against human gastric cancer. The immunoliposomes were characterized in vitro and in vivo with different nude mouse xenograft models and different routes of administration. The immunore activity was well preserved. The diameter was 100nm for reverse-phase evaporation vesicles and 35nm for small unilamellar vesicles. 1,000-10,000 molecules of antitumor agent were entrapped and 30-80 molecules of MGb2 incorporated per one liposome. They showed selective cytotoxicity to human gastric cancer cell SGC-7901 but very low toxicity to human normal embryonic lung cell SL7. Biodistribution studies indicated that both were better than non-specific liposomes and free drugs. Boronated immunoliposomes could carry boron-10 specifically to SGC-7901 and showed targeted boron neutron capture therapy effects after thermal neutron irradiation. The results confirmed the specific antitumor effects of immunoliposomes in vitro and in vivo and demonstrated the potentiality of the immunoliposomes in the targeting therapy of human gastric cancer.
Xu
L
L
Center of Gastroenterology, Xijing Hospital, Fourth Military Medical University, Xi'an.
Zhang
X Y
XY
Zhang
S Y
SY
D000818:Animals; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016754:Boron Neutron Capture Therapy; D004337:Drug Carriers; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D008081:Liposomes; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000532:radiotherapy / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004337:Drug Carriers; D000922:Immunotoxins; D008081:Liposomes